论文部分内容阅读
18例初诊2型糖尿病患者在使用那格列奈和吡格列酮治疗1个月前后,分别进行口服糖耐量试验,测定各个时间点的血糖、胰岛素,计算口服葡萄糖刺激后HomaA胰岛素抵抗指数、HomaB胰岛素分泌指数,第30min与空腹时胰岛素差值(△I30)和血糖差值(△G30)的比值(△I30/△G30)。结果:患者经治疗后空腹和餐后2小时血糖明显降低(P<0.001),HomaA胰岛素抵抗指数也明显降低(P<0.01),而HomaB胰岛素分泌指数和△I30/△G30均较治疗前明显提高(P<0.001)。结论:使用那格列奈和吡格列酮治疗后,初诊2型糖尿病患者在有效降低血糖的同时,能减轻胰岛素抵抗,促进胰岛素的分泌,特别是早期相胰岛素的分泌。
18 patients with newly diagnosed type 2 diabetes mellitus were treated with nateglinide and pioglitazone for one month before and after oral glucose tolerance test. Blood glucose and insulin were measured at each time point. HomaA insulin resistance index, HomaB insulin secretion Index, the ratio of the difference between fasting insulin (△ I30) and blood glucose difference (△ G30) at the 30th minute (△ I30 / △ G30). Results: After treatment, the fasting blood glucose and postprandial blood glucose decreased significantly (P <0.001) and the HomaA insulin resistance index decreased significantly (P <0.01), while the HomaB insulin secretion index and △ I30 / △ G30 were significantly higher than those before treatment Increase (P <0.001). Conclusion: After treatment with nateglinide and pioglitazone, newly diagnosed type 2 diabetic patients can reduce insulin resistance and promote insulin secretion, especially early phase insulin secretion, while effectively lowering blood glucose.